The effect of AOD9604 on weight loss in obese adults: results of a randomized, double-blind, placebo-controlled, multicenter study
Herd C, Wittert G, Caterson L, Proietto J, Strauss B, Prins J, Stocks A, Vos E, +1 more
Obesity Research (NAASO Annual Meeting conference proceedings) (2005) · n=300
The Phase IIa AOD-9604 data — the 1 mg oral dose producing roughly 2.6–2.8 kg weight loss versus 0.8 kg on placebo across 12 weeks in 300 obese adults — was presented as a NAASO conference abstract in 2005 and never developed into a peer-reviewed full-paper publication. The marketing literature in 2026 still cites it as primary evidence.
This entry is the citation record for the AOD-9604 Phase IIa data (Metabolic Pharmaceuticals trial code METAOD005) that the 2026 marketing literature for the molecule still routinely cites as primary efficacy evidence. It is filed here as a conference-proceedings reference rather than a primary research paper because, on the available bibliographic record, that is what it is: the data were presented by Caroline Herd and the multicenter Australian investigator group at the North American Association for the Study of Obesity (NAASO) Annual Meeting and indexed in Obesity Research as conference proceedings in 2005. A corresponding peer-reviewed full-length journal publication of the METAOD005 efficacy results does not appear in PubMed or in the standard journal indexes as of 2026, and the integrated safety paper from Stier et al. 2013 summarises the trial dataset without superseding it with a primary efficacy publication.
The reported trial design, as reconstructed from the conference abstract, the contemporaneous Metabolic Pharmaceuticals corporate communications, and the trial-registry summary, was a 14-week protocol at five Australian centres: a 2-week single-blind placebo run-in followed by 12 weeks of daily oral dosing of AOD-9604 at 1, 5, 10, 20, or 30 mg or placebo in approximately 300 healthy obese adults (BMI ≥ 35 kg/m²). The headline reported result was that the 1 mg oral dose arm produced approximately 2.6 to 2.8 kg of weight loss across 12 weeks versus approximately 0.8 kg on placebo — a separation that, on a 12-week timescale at the smallest oral dose tested, encouraged the larger and longer Phase IIb investment (METAOD006) which subsequently did not differentiate any active dose arm from placebo on its primary endpoint.
This entry exists primarily to surface the structural problem the marketing literature obscures: the efficacy data cited for AOD-9604 in 2026 trace back to a conference abstract and corporate disclosures, not to a peer-reviewed journal publication of the Phase IIa efficacy results. The peer-reviewed publication in the AOD-9604 file is the safety summary, not the efficacy primary. The Phase IIb that ended the obesity development program never reached a peer-reviewed efficacy publication either.
This is a conference abstract, not a peer-reviewed primary research paper. The full trial methodology, primary endpoint specification, randomisation procedure, intention-to-treat analysis, and per-protocol completer analysis are not available in the form a Tier 1 source would require. The Phase IIa sample size (~300) is moderate for a conference-grade obesity signal but too small to settle the efficacy question that the Phase IIb (METAOD006) was designed to address. The result reported here — modest weight separation at the smallest dose tested — did not replicate in the larger and longer Phase IIb trial, which is the modal outcome when small Phase IIa effects dilute through tighter blinding, broader recruitment, and longer endpoint windows. The fact that no peer-reviewed efficacy publication has appeared in the two decades since the data were presented, despite continued commercial activity around the molecule, should itself be read as informative. The Stier 2013 safety paper gives the closest thing to a published trial summary; the /peptides/aod-9604 page and the /critic/aod-9604-fat-loss-claims response handle the marketing-versus-evidence reconstruction in detail. Treat this entry as a citation record for material the marketing literature uses, not as confirmed primary evidence.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.